BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 34556811)

  • 1. Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment.
    Moskovich D; Finkelshtein Y; Alfandari A; Rosemarin A; Lifschytz T; Weisz A; Mondal S; Ungati H; Katzav A; Kidron D; Mugesh G; Ellis M; Lerer B; Ashur-Fabian O
    Oncogene; 2021 Nov; 40(44):6248-6257. PubMed ID: 34556811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer.
    Moskovich D; Alfandari A; Finkelshtein Y; Weisz A; Katzav A; Kidron D; Edelstein E; Veroslavski D; Perets R; Arbib N; Kadan Y; Fishman A; Lerer B; Ellis M; Ashur-Fabian O
    Cancer Lett; 2021 Mar; 501():224-233. PubMed ID: 33221455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ROR2 induces cell apoptosis via activating IRE1α/JNK/CHOP pathway in high-grade serous ovarian carcinoma in vitro and in vivo.
    Li R; Liu T; Shi J; Luan W; Wei X; Yu J; Mao H; Liu P
    J Transl Med; 2019 Dec; 17(1):428. PubMed ID: 31878941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Fatty Acid Oxidation to Promote Anoikis and Inhibit Ovarian Cancer Progression.
    Sawyer BT; Qamar L; Yamamoto TM; McMellen A; Watson ZL; Richer JK; Behbakht K; Schlaepfer IR; Bitler BG
    Mol Cancer Res; 2020 Jul; 18(7):1088-1098. PubMed ID: 32198139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased type 3 deiodinase expression in papillary thyroid carcinoma.
    Romitti M; Wajner SM; Zennig N; Goemann IM; Bueno AL; Meyer EL; Maia AL
    Thyroid; 2012 Sep; 22(9):897-904. PubMed ID: 22823995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fascin1 expression in high-grade serous ovarian carcinoma is a prognostic marker and knockdown of fascin1 suppresses the proliferation of ovarian cancer cells.
    Park SH; Song JY; Kim YK; Heo JH; Kang H; Kim G; An HJ; Kim TH
    Int J Oncol; 2014 Mar; 44(3):637-46. PubMed ID: 24378809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low expression level of HMBOX1 in high-grade serous ovarian cancer accelerates cell proliferation by inhibiting cell apoptosis.
    Yu YL; Diao NN; Li YZ; Meng XH; Jiao WL; Feng JB; Liu ZP; Lu N
    Biochem Biophys Res Commun; 2018 Jun; 501(2):380-386. PubMed ID: 29709478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple direct and indirect mechanisms drive estrogen-induced tumor growth in high grade serous ovarian cancers.
    Ciucci A; Zannoni GF; Buttarelli M; Lisi L; Travaglia D; Martinelli E; Scambia G; Gallo D
    Oncotarget; 2016 Feb; 7(7):8155-71. PubMed ID: 26797759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a Bioluminescent BRCA1-Deficient Xenograft Model of Disseminated, High-Grade Serous Ovarian Cancer.
    Shen YT; Wang L; Evans JC; Allen C; Piquette-Miller M
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31117198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting P16INK4A in uterine serous carcinoma through inhibition of histone demethylation.
    Xiao Z; He Y; Liu C; Xiang L; Yi J; Wang M; Shen T; Shen L; Xue Y; Shi H; Liu P
    Oncol Rep; 2019 May; 41(5):2667-2678. PubMed ID: 30896884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo tumor growth of high-grade serous ovarian cancer cell lines.
    Mitra AK; Davis DA; Tomar S; Roy L; Gurler H; Xie J; Lantvit DD; Cardenas H; Fang F; Liu Y; Loughran E; Yang J; Sharon Stack M; Emerson RE; Cowden Dahl KD; V Barbolina M; Nephew KP; Matei D; Burdette JE
    Gynecol Oncol; 2015 Aug; 138(2):372-7. PubMed ID: 26050922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation and function of deiodinases during decidualization in female mice.
    Deng WB; Liang XH; Liu JL; Yang ZM
    Endocrinology; 2014 Jul; 155(7):2704-17. PubMed ID: 24797630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MAPK and SHH pathways modulate type 3 deiodinase expression in papillary thyroid carcinoma.
    Romitti M; Wajner SM; Ceolin L; Ferreira CV; Ribeiro RV; Rohenkohl HC; Weber Sde S; Lopez PL; Fuziwara CS; Kimura ET; Maia AL
    Endocr Relat Cancer; 2016 Mar; 23(3):135-46. PubMed ID: 26825960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective Killing of Cancer Cells Through ROS-Mediated Mechanisms by AMRI-59 Targeting Peroxiredoxin I.
    Yang YJ; Baek JY; Goo J; Shin Y; Park JK; Jang JY; Wang SB; Jeong W; Lee HJ; Um HD; Lee SK; Choi Y; Rhee SG; Chang TS
    Antioxid Redox Signal; 2016 Mar; 24(8):453-69. PubMed ID: 26528922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute downregulation of Type II and Type III iodothyronine deiodinases by photoperiod in peripubertal male and female Siberian hamsters.
    Kampf-Lassin A; Prendergast BJ
    Gen Comp Endocrinol; 2013 Nov; 193():72-8. PubMed ID: 23891658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 17. Functional proteomics interrogation of the kinome identifies MRCKA as a therapeutic target in high-grade serous ovarian carcinoma.
    Kurimchak AM; Herrera-Montávez C; Brown J; Johnson KJ; Sodi V; Srivastava N; Kumar V; Deihimi S; O'Brien S; Peri S; Mantia-Smaldone GM; Jain A; Winters RM; Cai KQ; Chernoff J; Connolly DC; Duncan JS
    Sci Signal; 2020 Feb; 13(619):. PubMed ID: 32071169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early Loss of Histone H2B Monoubiquitylation Alters Chromatin Accessibility and Activates Key Immune Pathways That Facilitate Progression of Ovarian Cancer.
    Hooda J; Novak M; Salomon MP; Matsuba C; Ramos RI; MacDuffie E; Song M; Hirsch MS; Lester J; Parkash V; Karlan BY; Oren M; Hoon DS; Drapkin R
    Cancer Res; 2019 Feb; 79(4):760-772. PubMed ID: 30563893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased expression of the thyroid hormone-inactivating enzyme type 3 deiodinase is associated with lower survival rates in breast cancer.
    Goemann IM; Marczyk VR; Recamonde-Mendoza M; Wajner SM; Graudenz MS; Maia AL
    Sci Rep; 2020 Aug; 10(1):13914. PubMed ID: 32807826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gain-of-Function Mutant TP53 R248Q Overexpressed in Epithelial Ovarian Carcinoma Alters AKT-Dependent Regulation of Intercellular Trafficking in Responses to EGFR/MDM2 Inhibitor.
    Lai ZY; Tsai KY; Chang SJ; Chuang YJ
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.